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Introduction: The relevance of the cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheimer’s disease
(AD) and related disorders is clearly established. However, the question remains on how to use these data, which
are often heterogeneous (not all biomarkers being pathologic). The objective of this study is to propose to
physicians in memory clinics a biologic scale of probabilities that the patient with cognitive impairments has an
Alzheimer’s disease (AD) pathologic process.
Methods: For that purpose, we took advantage of the multicenter data of our Paris-North, Lille, and Montpellier
(PLM) study, which has emerged through the initial sharing of information from these memory centers. Different
models combining the CSF levels of amyloid-β 42, tau, and p-tau(181) were tested to generate categories of
patients with very low (<10%), low (<25%), high (>75%), and very high predictive values (>90%) for positive AD. In
total, 1,273 patients (646 AD and 627 non-AD) from six independent memory-clinic cohorts were included.
Results: A prediction model based on logistic regressions achieved a very good stratification of the population but
had the disadvantages of needing mathematical optimization and being difficult to use in daily clinical practice.
Remarkably, a simple and intuitive model based on the number (from zero to three) of three pathologic CSF biomarkers
resulted in a very efficient predictive scale for AD in patients seen in memory clinics. The scale’s overall predictive value
for AD for the different categories were as follows: class 0, 9.6% (95% confidence interval (CI), 6.0% to 13.2%); class 1,
24.7% (95% CI, 18.0% to 31.3%); class 2, 77.2% (95% CI, 67.8% to 86.5%); and class 3, 94.2% (95% CI, 90.7% to 97.7%). In
addition, with this scale, significantly more patients were correctly classified than with the logistic regression. Its superiority
in model performance was validated by the computation of the net reclassification index (NRI). The model was also
validated in an independent multicenter dataset of 408 patients (213 AD and 195 non-AD).
Conclusions: In conclusion, we defined a new scale that could be used to facilitate the interpretation and routine use of
multivariate CSF data, as well as helping the stratification of patients in clinical research trials.Introduction
Intense research efforts have been conducted to develop
and validate biomarkers to predict, detect, and follow up
the progression of the disease or impact of potential new
disease-modifying treatments of Alzheimer’s disease (AD).
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scales or tools are available to physicians involved in AD
research for better interpreting the positive or negative re-
sults of biomarkers for establishing a clinical diagnosis,
such as the detection of hippocampal atrophy with the
Scheltens’ scale [4] and the positivity of amyloid load on
functional brain imaging via the Jack’s visual scale [5].
Although biologic cerebrospinal fluid (CSF) bio-
markers are among the most studied and validated in
clinical practice [6-8], no sort of “visual” scale concerningral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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indeed show that AD patients display characteristic
CSF changes with decreased levels of β-amyloid1-42
(Aβ42) and elevated levels of total tau protein (tau)
and its phosphorylated form at threonine 181 (p-tau)
[7,9,10]. Interestingly, these biomarkers are directly related
to neuropathologic changes [11] present in the disease.
Therefore, one would expect that the presence of these
three biomarkers would be highly indicative of AD,
whereas their absence would strongly disqualify this
diagnosis. Other biomarkers represented by isoforms
of Aβ (Aβ40, Aβ38) or linked to oxidative stress and in-
flammation [12,13] may also contribute to the diagnosis of
AD, in particular when combined with tau or Aβ42. Apart
from familial forms of AD, genetic profiles [14], in particu-
lar apolipoprotein E status, which represents the most
prominent risk factor, is not yet used as a diagnostic tool.
So, today we can only rely routinely on the commonly
measured CSF biomarkers Aβ42, tau, and p-tau to help
us with AD diagnosis. In clinical practice, after control
of preanalytic biases [15-17] and standardization of pro-
cedures [18-20], the performance of CSF biomarkers is
satisfactory with a coupled sensitivity/specificity as high
as 80% when used alone or combined. The combination of
these biomarkers increases their performance, as demon-
strated for Aβ42 and tau [21] or Aβ42 and p-tau [22,23]. In
most AD biomarker studies, results are represented by the
best sensitivity/specificity and area under the ROC curves
(AUC). It is, however, difficult to use this information dir-
ectly when biomarkers are being used in routine practice to
help physicians with AD diagnosis [6-8]. We need a way to
convert the variation of the three biomarkers into a prob-
ability scale for AD. A leading study from Spies et al. [24]
proposed a logistic regression of logarithmic-transformed
values of Aβ42 and p-tau values and sex defined classes of
AD probability. Logistic regressions already demonstrated
their relevance in differentiating AD patients from non-AD
patients [7,23].
In the present study, we conducted an evaluation, based
on multicenter data from our PLM cohort [25], of a simpler
scale based solely on the numbers (from 0 to 3) of patho-
logic biomarkers (Aβ42, tau, and p-tau) identified. This
intuitive scale was very efficient for generating categories of
patients seen in memory clinics with a refined probability
of AD, and it will represent a valuable tool for facilitating
the interpretation and routine use of multivariate CSF data
for stratifying patients into clinical research trials.
Material and methods
Study design and subjects
Patients (1,273) who had a lumbar puncture were recruited
between January 2008 and December 2011 from the three
initial PLM centers (Paris-North, Lille, and Montpellier)
specialized in the care management of patients withcognitive disorders (Table 1). These centers used the same
diagnostic procedures and criteria [25]. All patients had a
thorough clinical examination, including biologic laboratory
tests, neuropsychological evaluations, and brain imaging.
Patients were classified into two groups: AD (as defined by
the NINCDS-ADRDA criteria [26]), and non-AD (NAD)
patients. NAD diagnosis (that is, frontotemporal lobar de-
generation, semantic dementia, Lewy body and Parkinson
diseases, progressive supranuclear palsy, amyotrophic lat-
eral sclerosis, normal-pressure hydrocephalus, and psychi-
atric disorders), were defined by the commonly validated
international criteria. Important for this study, the used
diagnostic criteria for AD do not include CSF biomarkers
(otherwise, that would bias the evaluation of the interest of
the scale, which was based on biomarker values). Mild cog-
nitive impairment, as well as phenotypes that were mixed
with AD or might correspond to specific/early forms of
AD, were excluded from the cohorts (mixed dementia,
primary progressive aphasia, amyloid angiopathy). CSF was
collected by using standardized collection, centrifugation,
and storage conditions in different centers [25].
A second set of data from 408 patients with the same
clinical characteristics was generated from the three
new PLM centers (Rouen, Strasbourg, and Besançon)
also specialized in the care management of patients
with cognitive disorders.
CSF samples and assays
CSF Aβ42, tau, and p-tau concentrations were measured
by using standardized commercially available INNOTEST
sandwich ELISA, according to the manufacturer’s proce-
dures (Fujirebio Europe NV, formerly Innogenetics NV).
As the data were generated in the different centers
through the routine activity of their laboratories, the
lots of assay kits were variable within and in between
laboratories. The quality of the results was ensured by
the use of validated standard operating procedures and
internal quality controls (QCs). The range of the QC coef-
ficient of variation for Aβ42 across the different lots for
the six laboratories was 5% to 11%. For tau and p-tau, the
range was 8% to 14% and 6% to 14%, respectively. The use
of external QC ensured also the quality of the results and
the validity of the intersite data comparison [19]. The Paris,
Lille, and Montpellier centers contributed with two sets of
data labeled “-1” or “-2” generated from different collection
tubes (for the −1 cohort in Montpellier, Greiner, catalog
number 18 82 81; in Lille, Becton Dickinson, catalog
number Falcon 35 2097; in Paris, CML, catalog number
TC10PCS, and for the −2 cohorts: Sarstedt, catalog number
62.610.201) [20]. These two sets of data differed in their op-
timal cutoffs (≤506 and ≤834 for Aβ42; >343 and >340 for
tau; >64 and >62 for p-tau; see Additional file 1) in relation
with the preanalytic properties of the tube that affected
mostly Aβ42 levels [27].
Table 1 Population demography and biomarker values
Paris-1 Paris-2 Lille-1 Lille-2 Montpellier-1 Montpellier-2 RSB
AD n = 118 Mean SD AD n = 41 Mean SD AD n = 118 Mean SD AD n = 73 Mean SD AD n = 129 Mean SD AD n = 142 Mean SD AD n = 213 Mean SD
Age 73.6 8.8 Age 70.9 8.9 Age 68.3 9 Age 67 9.5 Age 69.7 8.8 Age 71.1 10.1 Age 66.3 8.7
Aβ42 440 189 Aβ42 594 238 Aβ42 338 162 Aβ42 603 245 Aβ42 505 224 Aβ42 654 256 Aβ42 420 224
Tau 598 295 Tau 543 279 Tau 608 336 Tau 778 364 Tau 611 327 Tau 702 727 Tau 666 407
p-tau 99 40.4 p-tau 86 34 p-tau 98.1 46.9 p-tau 101.5 41.2 p-tau 85.9 40.2 p-tau 86 37.7 p-tau 92.4 38.1
MMSE 19.4 5.6 MMSE 18.7 6.7 MMSE 18.1 6.5 MMSE 19.6 6.3 MMSE 21.9 5.5 MMSE 20.7 7.4 MMSE 19.0 6.1
Sex (%M) 47% sex (%M) 65% sex (%M) 37% sex (%M) 47% sex (%M) 47% sex (%M) 49% sex (%M) 50%
NAD n = 53 Mean SD NAD n = 68 Mean SD NAD n = 128 Mean SD NAD n = 51 Mean SD NAD n = 215 Mean SD NAD n = 147 Mean SD NAD n = 195 Mean SD
Age 62.1 13.1 Age 67.4 11.1 Age 67.3 10.7 Age 64.6 10.7 Age 64.1 13.6 Age 63.4 13.6 Age 65.4 10.1
Aβ42 686 243 Aβ42 843 246 Aβ42 494 192 Aβ42 974 355 Aβ42 706 266 Aβ42 999 373 Aβ42 723 346
Tau 253 226 Tau 223 141 Tau 273 197 Tau 284 149 Tau 291 233 Tau 310 241 Tau 339 258
p-tau 48.6 23.1 p-tau 43.5 19.3 p-tau 52.6 28.7 p-tau 46.5 15.8 p-tau 44.8 23.7 p-tau 38.4 18.6 p-tau 49.3 25.8
MMSE 23 5.3 MMSE 23.6 4.9 MMSE 21.3 5.5 MMSE 21. 2 6 MMSE 20.7 7.1 MMSE 21.1 6.9 MMSE 21.0 6.1
Sex (%M) 53% Sex (%M) 49% sex (%M) 51% sex (%M) 59% sex (%M) 53% sex (%M) 55% sex (%M) 51%
Mean and standard deviation of demographic data, CSF biomarker levels (Aβ42, tau, and p-tau) and Mini Mental Score (MMSE) for the patients with AD or NAD diagnosis in the different centers (Montpellier, Lille, Paris)
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centers (Rouen, Strasbourg, and Besançon), which used
standard cutoff biomarker values in relation to the type
of collection tube used [20]. The lumbar puncture, the
CSF biomarkers measurement, and the clinical examination
(including the diagnosis) were part of standard care.
This observational study on routine biologic analyses is
not considered in France to be “biomedical research,”
and it does not necessitate informed consent or ethical
approval. Authorization for handling personal data has
been granted by the French Data Protection Authority
(CNIL) under the number 1709743 v0.
Statistical analysis
Statistical analyses were computed with the MedCalc
software (11.3). The logistic regression was performed
by following a method similar to that of Spies et al. [24].
In brief, log-transformed CSF biomarkers and sex were
entered with backward stepwise selection by using a signifi-
cance level of 0.10. The logistic regression generates the co-
efficients of a formula to predict the logistic transformation
of the probable presence of AD (p(AD)) as follows:
p(AD) = 1/(1 + 1 e – [intercept + score])
where score = coefficient × ln(Aβ42) + coefficient × ln
(p-tau) + coefficient × Sex. Probability classes to discriminate
between AD and non-AD patients were obtained by select-
ing the following ranges of p(AD): class 0, 0 to 0.1; class 1,
0.1 to 0.5; class 2, 0.5 to 0.9; and class 3, 0.9 to 1.0.
We did not perform the logistic regression analysis
in one training population with the goal to apply the
resulting classification to the other populations, but we
rather recalculated the coefficients in each cohort to
generate best-fitted models. Receiver operating charac-
teristic (ROC) curves were used to represent sensitivity
and specificity for AD detection. ROCs are generated
from continuous diagnostic variables. The CSF biomarkers
and their ratio are continuous, as well as the p(AD) values
obtained after the logistic regression. Regarding the scales,
we plotted the curve by using the four values 0, 1, 2,
and 3 applied to the different samples.
To compare the classifications of patients, we used the
net reclassification index (NRI) [28]. The NRI is based
on reclassification constructed separately for participants
with and without the event of interest (that is, AD or
non-AD diagnosis), and quantifies the correct movement
into classes, upward for events and downward for non-
events. At first, the following probabilities were calcu-
lated: p(up_AD) = (number of cases in which the class
was moving up between two classifications of AD patients)/
(number of AD patients); p(down_AD) = (number of cases
in which the class was moving down between two
classifications of AD patients)/(number of AD patients);
p(up_NAD) = (number of cases in which the class was
moving up between two classifications of NAD patients)/(number of NAD patients); p(down_NAD) = (number of
cases in which the class was moving down between two
classifications of NAD patients)/(number of NAD patients).
We assumed that correctly classifying an AD patient was as
important as correctly classifying an NAD patient, and there-
fore we computed the NRI by using the formula: NRI =
(p(up_AD)-p(down_AD))-(p(up_NAD)-p(down_NAD)).
Results
Demographics and biomarker values for the different
cohorts are presented in Table 1. As expected, differences
in individual biomarker concentrations between AD and
NAD were apparent across all cohorts. ROC curves for
Aβ42, tau, and p-tau were used to compute AUCs (Table 2)
and optimal cutoff values (Additional file 1). AUCs were
also calculated for Aβ42/tau and Aβ42/p-tau ratios, as
well as the Aβ/tau index (IATI) [21] (Table 2). The Paris,
Lille, and Montpellier PLM centers provided data from two
independent cohorts (−1 and −2) that differed by the type
of collection tube used (see Material and methods section).
This explains the variations in cutoff values; the second
tube having been selected for its low Aβ42 absorption [27],
therefore resulting in higher cutoff values [20]. All patients
of these three centers for whom samples were collected in
tube 1 or 2 were also differentiated into two additional
populations called PLM-1 and PLM-2. This was one way
to evaluate the AD scale on multicenter cohorts after
standardization of biologic and clinical practices. Data
from these populations were used to compare predictions
based on a logistic regression performed as shown by
Spies et al. [24]. Interestingly, sex was never retained in
the model used for our cohorts (Additional file 1). The
models were very efficient in differentiating AD from non-
AD (NAD) patients for all cohorts with AUCs close to 0.9
in most cases (Table 2).
The distribution of AD and NAD patients was then
evaluated according to four classes: between p(AD) 0 to
0.1 for class 0; 0.1 to 0.5 for class 1; 0.5 to 0.9 for class 2;
and 0.9 to 1 for class 3 (Figure 1A,B and Additional file 2).
The percentage of AD in each class was also computed
(Figure 1C). As expected, in class 0, we found only around
10% of AD patients, whereas in class 3, this number was
close to 90%, with slight variations related to differences
in AD prevalence in these populations (Table 1).
The PLM scale composed of four classes was then
designed, based on a very simple and intuitive rule:
class 0, corresponding to no pathologic biomarkers
(below cutoff for Aβ42, above cutoff for tau and p-tau);
class 1, corresponding to one pathologic biomarker of
three; class 2, corresponding to two pathologic biomarkers
of three; and class 3, with all three biomarkers being patho-
logic. We calculated the sensitivity and specificity of this
scale, with classes 0 and 1 grouped on one side, and classes
2 and 3, on the other side for NAD and AD diagnoses,
Table 2 AUCs
AUC Paris-1 Paris-2 Lille-1 Lille-2 Mtp-1 Mtp-2 PLM-1 PLM-2 Mean
Aβ42 0.81 0.768 0.778 0.826 0.747 0.778 0.772 0.787 0.783
Tau 0.898 0.921 0.869 0.905 0.84 0.852 0.86 0.88 0.878
p-tau 0.911 0.913 0.87 0.917 0.842 0.91 0.875 0.912 0.894
IATI 0.902 0.895 0.858 0.917 0.827 0.877 0.855 0.896 0.878
Aβ42/tau 0.913 0.921 0.88 0.927 0.849 0.882 0.874 0.905 0.894
Aβ42/p-tau 0.923 0.92 0.875 0.92 0.86 0.924 0.884 0.924 0.904
Logi. reg. 0.926 0.928 0.892 0.936 0.869 0.933 0.896 0.932 0.914
Log. reg. scale 0.917 0.931 0.872 0.927 0.838 0.918 0.876 0.919 0.900
PLM scale 0.94 0.931 0.887 0.919 0.863 0.933 0.883 0.924 0.910
Area under the ROC for the individual biomarkers Aβ42, tau and p-tau, the IATI [21] and the ratios Aβ42/tau and Aβ42/p-tau. The values of the p(AD) obtained
after logistic regression were also used to calculate the AUC. The logistic regression values were separated into four classes (0 to 3), which values were then used,
just as for the PLM scale, to calculate the AUCs.
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for AD if two or three biomarkers were pathologic
(class 2 or 3). The performance of this simple rule was very
high, as demonstrated by the sensitivity and specificity
reached across the different cohorts (see Additional file 2).
Moreover and interestingly, when all AUCs were com-
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Figure 1 Distribution and percentage of the AD and NAD patients be
the distribution of the AD (A) and NAD (B) patients in the Paris, Lille, and M
regression or the PLM scale. Significant differences (Student t test) were fou
well as between the percentage of NAD patients in classes 0 and 1 (B). (C)
plotted. No significant difference was apparent. (D, E) The distribution of AD
the Rouen, Strasbourg, and Besançon (RSB) centers. The percentage of AD in
by using the PLM scale (C) show more AD patients in class 3 and NAD in clasDistributions of AD and NAD patients, as well as percent-
age of AD patients in each class, were then computed and
plotted for the PLM scale (Figure 1A-C; Additional file 2).
The percentage of AD patients in each class, which actually
corresponded to the positive predictive value (PPV), that is,
the percentage of true positives among all samples in the
class, was compared between the two prediction models
(Figure 1C). Predictive values were not significantly differentE
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% of AD patients
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(dark gray bars) and NAD (light gray bars) patients in the populations of
each class is also plotted (black dots linked a dotted line). Data obtained
s 0 than for the logistic regression (E).
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For the PLM scale, the average predictive values for AD in
these cohorts were for class 0, 9.6% (95% CI, 6.0% to 13.2%);
for class 1: 24.7% (95% CI, 18.0% to 31.3%), for class 2:
77.2% (95% CI, 67.8% to 86.5%), and for class 3, 94.2%
(95% CI, 90.7% to 97.7%) (Figure 2).
The difference in patient distribution between the two
prediction models was, however, significantly different,
as the PLM scale had more AD patients in class 3 as well
as more NAD patients in class 0 compared with the predic-
tion obtained with the logistic regression (Figure 1A, B).
This distribution of AD and NAD patients in different
classes was also evaluated in an additional dataset from
Rouen Strasbourg and Besançon (RSB) centers (Table 1).
We used the standard cutoffs and logistic regression co-
efficients (Additional file 2) to compute and represent
in Figure 1 (panels D and E) the distribution of AD and
NAD patients across the different classes, as well as the
percentage of AD patients in each class. With the PLM
scale, profiles were comparable to those obtained before,
with a better distribution of patients (more AD patients in
class 3, and more NAD patients in class 0) and similar
percentages of AD patients in each class.
To compare the classification resulting from the logis-
tic regression and the PLM scales, we calculated the NRI
(see Material and methods section) on the PLM-2 popula-
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Figure 2 Graphic illustration of the AD scale.more patients better classified (that is, having a higher scale
value in the case of AD patients, and a lower value for non-
AD patients). Similar results were obtained when the NRI
was applied to the different cohorts (data not shown).
Discussion
Diagnostic measures of AD include clinical observation,
assessment of cognitive functions, including memory test-
ing as well as advanced neuroimaging examinations such as
magnetic resonance imaging (MRI) or positron emission
tomography (PET), and CSF biomarkers [29]. In the present
study, we validated the relevance of CSF biomarkers when
used individually or within ratios [7,21-23]. Identifying one
or several biomarkers or ratios as pathological is clinically
relevant for the diagnosis of AD. However, the question re-
mains as to how to use this element, which is often hetero-
geneous (not all biomarkers being pathological) in clinical
practice. This complexity renders problematic the inter-
pretation of biomarker results, and it differs between
practitioners or centers.
Different rating systems or scales have being designed
to help clinicians evaluate dementia. The clinical dementia
rating (CDR), which is a 5-point scale based on cognitive
and functional performances, does provide valuable clinical
information [30]. The medial temporal lobe atrophy visual
rating scale introduced by Scheltens et al. [31] is also a
good example of a biomarker scale facilitating the diagnosis 1 Class 2 Class 3
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into a score that predicts clinical outcomes. This was re-
cently done to predict the conversion of mild cognitive
impairment (MCI) patients into AD by using CSF Aß42,
MRI, and PET data [32]. However, this model cannot be
applied to our paradigm, which focuses on memory
clinic cohorts suspected of having AD or other differen-
tial dementia diagnoses. Very relevant in this context is
the leading work of Spies et al., [24] who used a logistic
regression on CSF biomarkers and sex to define a pre-
dictive model for AD. This model reached the highest
performance for the diagnosis of AD, and it provides a
continuous predictive scale made of 10 classes of AD
probability (that is, none to 10%, 10% to 20%).
When we reproduced this approach for our datasets,
the logistic regression did not retain sex in the models.
The higher percentage of women in the AD population
in the Spies cohort was probably responsible for this
difference. In any case, the performance of the logistic
regression was outstanding, as it resulted in the highest
AUCs among individual or biomarker ratios (Table 2).
To match the reports already used in clinical practice,
we wanted to generate a simple rating with classes
bearing very low (<10%), low (<25%), high (>75%), and
very high predictive values (>90%) for AD. Four logistic
regression classes with p(AD) ranging from 0 to 0.1,
0.1 to 0.5, 0.5 to 0.9, and 0.9 to 1 were therefore generated.
This resulted in classes having an expected percentage of
AD prediction (Figure 1C). We then compared this logistic
regression approach with an intuitive classification based
solely on the numbers (from 0 to 3) of pathological CSF
biomarkers (Aß42, tau, and p-tau) (Figure 2).
The performance of this simple scale was evaluated
in the different cohorts by using as a criterion of AD
the presence of two or three pathologic biomarkers.
Surprisingly, this simple rule resulted in high sensibility/
specificity/AUCs. The predictive values of this “PLM scale”
for the different classes were also similar to the ones
obtained with the logistic regression (Figure 1C). Dif-
ferences in the distribution of AD and NAD patients
between classes were, however, noticeable, with signifi-
cantly more patients correctly classified with the PLM
scale. This apparent superiority of the PLM scale was
validated by computing the NRI, which is a statistical
tool designed to assess improvement in model per-
formance offered by a new classification. This result
could be explained by the “discontinuous” nature of
the PLM scale, which is better suited to the four prob-
ability classes that we had targeted. Of note, a discrepancy
between predicted and observed percentage of AD in
regression classes was already observed by Spies et al. [24].
This triggered these authors to generate a second model
with an extensive correction based on a second regression.
This fine-tuning might overfit the models based on theindividuals within a cohort, and it is therefore not
adapted for the use of the scale in a predictive way for
the classification of new patients in memory clinics.
In any case, the PLM scale outperformed the logistic
regression and has the advantage of being used without
complex mathematical adjustments. In addition, this classi-
fication gave a direct access to the percentage of discarding
profiles, that is, AD patients with none of the biomarkers
being positive (class 0), and conversely, NAD patients with
three biomarkers being positive (class 3).
One of our study’s limits resides in using as reference
the final clinical diagnosis, which, in the absence of neuro-
pathologic information ,can sometimes remain uncertain.
However, diagnoses were established by experienced multi-
disciplinary teams based on clinical, neuropsychological,
and imaging data. The cross-validation of the results in the
different cohorts also guarantees the reliability and rele-
vance of our conclusions. Of note, the scale relies on the
use of biomarker cutoffs that might differ in the different
centers. The continuous improvement of the quality of
the assays, thanks to the use of quality control, and the
homogenization of preanalytics and operating procedure
[15-20] may result in a scale that will use “unified” cutoffs.
It is important to underline that the predictive value of the
PLM scale is valid only to evaluate whether memory im-
pairments or dementia is due to AD for patients seen in
memory clinics. In other situations, and in particular for
assessing the conversion from MCI to AD, the design and/
or predictive value of the PLM scale should be revaluated.
We also must keep in mind that if we expect the dis-
tribution of AD and NAD patients across classes to be
comparable between cohorts, the predicted percentage
of AD patients in a given class depends itself on the
prevalence of AD patients in the studied cohort. In the
future, this scale might be improved by adding new
variables and, in particular, the apolipoprotein E status,
which today is not used routinely.
Conclusion
We developed a simple and intuitive prediction model
that demonstrated its relevance in identifying groups of
patients with different predictive values for AD. This
new scale can be used to facilitate the interpretation and
routine use of multivariate CSF data and to stratify patients
in clinical research trials.
Additional files
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Additional file 2: Logistic regression and PLM scale classification.
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Association; NRI: Net Reclassification Index; PET: positron emission
tomography; PLM: Paris-North, Lille, and Montpellier; QC: quality control;
ROC: receiver operating characteristic.
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